Company Developments - Bayer's new oral anticoagulant Asundexian has completed Phase 3 clinical trials and is expected to receive FDA approval by the end of 2026, viewed as a key product with blockbuster potential [2] - The company plans to achieve five significant milestones in the first half of 2026, focusing on expanding indications for existing products and releasing new data to strengthen its position in innovative drug development [2] Strategic Initiatives - Bayer's Dynamic Shared Responsibility (DSO) operational model, initiated in 2023, aims to save €2 billion annually starting in 2026 through organizational streamlining and improved decision-making efficiency [3] - The company will continue to focus on four strategic areas: innovation, addressing litigation issues in the U.S., improving cash flow, and enhancing profitability in its crop science business, with the pharmaceutical sector (especially in oncology, cardiovascular, neuroscience, and rare diseases) seen as a core growth engine [3] Company Status - Bayer has divested non-core assets, such as the global business of the antibiotic moxifloxacin, to concentrate resources on its more promising innovative drug pipeline [4] Future Outlook - Bayer's core products, rivaroxaban (Xarelto) and aflibercept (Eylea), will continue to face sales pressure from generic competition in 2026, although the company anticipates that this pressure will gradually ease after 2026 [5] - Ongoing litigation related to glyphosate from the acquisition of Monsanto remains a significant uncertainty that requires continuous monitoring [6]